By next August there will be enough vaccine doses inventory to support the vaccination strategy designed by Cuba against Covid-19, and availability of products for collaboration with the rest of the interested nations, informed Eulogio Pimentel Vázquez, vice-president of BioCubaFarma.
Speaking on the radio program Mesa Redonda, the specialist added that the productive, industrial and technological strategy of the antidote proposals against the new coronavirus was designed in such a way that the Soberana vaccines would not interfere in the route of Abdala and Mambisa, since they use different industrial facilities, anchored to independent biotechnological centers.
He specified that this was done not to avoid competition, but in order to achieve better results in the shortest possible time, with different proposals and bets.
Vaccination against Covid-19 from joint efforts
The Doctor of Science highlighted the profound interaction between the above-mentioned Business Group, the Public Health system and its companies, deeply articulated for this purpose: to ensure the vaccination of the whole Cuban population.
He also highlighted the high quality of the laboratories, facilities and procedures through which it is possible to obtain results in the study of Cuban vaccine candidates with the availability of technological resources at the level of developed countries.
Soberana 02 began its Phase III at the beginning of March, and is a multicenter, adaptive, parallel-group, randomized, placebo-controlled, double-blind study in volunteers between 19 and 80 years of age, with no known history of SARS-CoV-2 infection.
The Abdala Phase III clinical trial is being conducted in the provinces of Santiago de Cuba, Granma and Guantanamo from March 22 to April 9, and involves 48,000 people between 19 and 80 years of age in a randomized, double-blind study, with a control group that will also be given placebo.
Among the 22 Covid-19 vaccines worldwide in Phase III clinical trials, two are the Cuban Abdala and Soberana 02; the country also has the candidates Soberana 01, Mambisa and Soberana Plus in primary phases of clinical trials.
Cuba is the only Latin American and Third World nation to have reached this important step.
(Taken from ACN)
Edited by Jorge Luis Lora Moran